What is the BCG Human Clinical Trial Program?

Led by Dr. Denise Faustman at Massachusetts General Hospital, the **BCG Human Clinical Trial Program** is testing Bacillus Calmette-Guérin (BCG), as a **treatment for longstanding type 1 diabetes**. The goal is to bring forward a new, inexpensive, non-toxic treatment for patients who have been living with type 1 diabetes for many years.

What did the Phase I human trial show?

Data from the first human study show that BCG may be a **promising treatment for advanced type 1 diabetes**. In this double-blind, placebo-controlled study, BCG was administered to adults who had been living with type 1 diabetes for an average of 15 years. BCG was shown to be **safe for people with type 1 diabetes**, with no severe reactions to the vaccine and only mild inflammation at the injection site, as expected. In addition, BCG treatment not only **helped to eliminate the “bad” white blood cells** that contribute to type 1 diabetes, but it also temporarily **restored the ability of the pancreas to produce small amounts of insulin**—an exciting finding in people who had been living with type 1 diabetes for so long!

What is the Phase II study?

A Phase II study is currently underway at Massachusetts General Hospital. The goal of this randomized, double-blind, placebo-controlled study is to see if repeat injections of BCG can **benefit people with longstanding type 1 diabetes** by putting the disease into remission and helping to **prevent diabetic complications**. The Phase II study will include approximately **150 people** with longstanding type 1 diabetes, ages 18-65. Participants will receive 2 injections of either **BCG or placebo** spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years. Over the course of the study, the investigators will see whether BCG vaccination is associated with **improvements in HbA1c** and look for **beneficial changes in autoimmune status**, such as continued elimination of the bad white blood cells that attack the pancreas.

Why test BCG in type 1 diabetes?

BCG is a **generic drug** that has been used for **nearly a century** in different ways, including as an anti-tuberculosis vaccine and as a bladder cancer treatment. BCG is derived from a strain of bacteria that is weakened so that it cannot make humans sick, but is still strong enough to prompt an immune response—including production of a natural substance in the body called **tumor necrosis factor (TNF)**. This response may be able to help **halt the disease process** in advanced type 1 diabetes. In preclinical studies, and in a Phase I human clinical trial, the Faustman Lab has shown that temporarily elevating TNF levels can **eliminate the “bad” white blood cells** (those that mistakenly attack and destroy the healthy cells of the pancreas that secrete insulin) in type 1 diabetes, which may have clinical benefits.

**References**


**How to Support This Program**

Philanthropy is a vital part of our program to **reverse advanced type 1 diabetes**. Please help us move these human studies forward with a tax-deductible donation.

1. To make a secure online donation, please visit [www.faustmanlab.org](http://www.faustmanlab.org) and click on “Support.”
2. Donations by check, payable to “Massachusetts General Hospital” (subject line “Faustman Diabetes Trials”) can be mailed to:

**Diabetes Clinical Trial**
c/o Dr. Denise Faustman
Immunobiology Laboratory
Massachusetts General Hospital-East Building 149, 13th Street, CNY-3601
Charlestown, MA 02129

**Support**

Thank you for joining us in the fight against diabetes!

- [diabetestrial@partners.org](mailto:diabetestrial@partners.org)
- 617-726-4084
- @FaustmanLab
- [www.facebook.com/FaustmanLab](http://www.facebook.com/FaustmanLab)

**To learn more visit [faustmanlab.org](http://faustmanlab.org)**

**Researching a cure for type 1 diabetes**